ACADIA Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
Thank you for joining us for this next session. My name is Nevin Varghese with RBC Capital Markets. I'm here joined by ACADIA Pharmaceuticals, Mark Schneyer, Thomas Garner, and Sanjeev Pathak. Yeah, let's get right into it. I know a lot of these conversations usually start out with looking at the commercial trajectory of NUPLAZID and DAYBUE, and I promise we'll get to that as well. But I think the key focus on a lot of investor minds recently has been remlifanserin.
So I'd love to start with that. And maybe you can talk about some of the preclinical differences that you've seen in remlifanserin versus pimavanserin, and some of the properties there that could enable this next generation to potentially show some efficacy in ADP, as well as what you've seen from the prior pimav trials that give you that confidence as well.
Okay, great question, first of all. The biggest difference between remlifanserin
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
